Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983.

导出 LinkOut

翻译打印收藏纠错

作者： Erik,Tanis ^[1] ; Catherine,Julié ^[2] ; Jean-Francois,Emile ^[2] ; Murielle,Mauer ^[3] ; Bernard,Nordlinger ^[2] ; Daniela,Aust ^[4] ; Arnaud,Roth ^[5] ; Manfred P,Lutz ^[6] ; Thomas,Gruenberger ^[7] ; Fritz,Wrba ^[7] ; Halfdan,Sorbye ^[8] ; Wolf,Bechstein ^[9] ; Peter,Schlag ^[10] ; Annette,Fisseler ^[11] ; Theo,Ruers ^[12]

作者单位： EORTC headquarters, Brussels, Belgium; The Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: eriktanis@gmail.com. ^[1] CHU Ambroise Pare, Paris, France. ^[2] EORTC headquarters, Brussels, Belgium. ^[3] Universitatsklinikum Dresden, Dresden, Germany. ^[4] University of Geneva, Geneva, Switzerland. ^[5] Caritas Klinikum, Saarbrucken, Germany. ^[6] Rudolfstiftung Hospital, Vienna, Austria. ^[7] Haukeland University Hospital, Bergen, Norway. ^[8] Klinikum der Johann-Wolfgang-Goethe-Universität, Frankfurt am Main, Germany. ^[9] Charité Campus Buch/ECRC and MDC, Berlin, Germany. ^[10] Dr. Horst Schmidt Kliniken, Wiesbaden, Germany. ^[11] The Netherlands Cancer Institute, Amsterdam, The Netherlands. ^[12]

关键词 B-lymphocytes Chemotherapy response Colorectal liver metastases Immune profile Macrophages Mast cells T-lymphocytes